title: Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treated with bevacizumab.
authors.affiliation: Istituto Giannina Gaslini, Genova, Italy. giovannimorana@ospedale-gaslini.ge.it
authors.forename: Giovanni
authors.initials: G
authors.lastname: Morana
authors.forename: Arnoldo
authors.initials: A
authors.lastname: Piccardo
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Garrè
authors.forename: Paolo
authors.initials: P
authors.lastname: Nozza
authors.forename: Alessandro
authors.initials: A
authors.lastname: Consales
authors.forename: Andrea
authors.initials: A
authors.lastname: Rossi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D002675:Child, Preschool; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D018450:Disease Progression; D005260:Female; D005462:Fluorine Radioisotopes; D018303:Ganglioglioma / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D008279:Magnetic Resonance Imaging; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D000077204:Temozolomide
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D000068258:Bevacizumab; C029112:5-fluorodopa; D004295:Dihydroxyphenylalanine; D003606:Dacarbazine; D000077204:Temozolomide